{
  "documentMetadata": {
    "title": "Francisella tularensis, Tularemia",
    "lastUpdated": "2024-10-07",
    "sourceFile": "Francisella tularensis, Tularemia.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Francisella tularensis causes a variety of infections as a consequence of:",
        "Direct contact with infected tissues of infected animals (hunters, farmers, veterinarians, landscapers, and meat handlers)",
        "Inhalation of infected aerosol (hazard to clinical microbiologists)",
        "Exposure to an infected biting insect (ticks, mosquitoes, deer and horse flies, and fleas)",
        "Tularemia: Clinical illness can vary from asymptomatic to septic shock and death;",
        "in aerosol form, a potential agent of bioterrorism.",
        "Tularemia bioterrorism reference: [N Engl J Med 372:954, 2015](https://www.nejm.org/doi/full/10.1056/NEJMra1401205).",
        "F. tularensis can cause one or more of several clinical syndromes:",
        "Ulceroglandular: most common presentation",
        "Oculoglandular",
        "Glandular",
        "Pharyngeal (oropharyngeal)",
        "Pneumonia",
        "Typhoidal (fever and hypotension)",
        "Meningitis",
        "For complications, see Comments.",
        "References:",
        "CDC-sponsored supplement: Tularemia: Update on Treatment and Clinical Findings: [Clin Infect Dis 2024; 78(:S1): S1-S75](https://academic.oup.com/cid/issue/78/Supplement_1)"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Laboratory diagnosis is difficult:",
        "Faintly staining, strictly aerobic, coccobacilli",
        "Rarely see on gram-stain; fastidious, may need special media, Colonies may require up to 3 days to be visible on culture plates",
        "Notify lab for both use of special culture media and to prevent infection of lab technologists",
        "Four-fold rise in antibody confirms diagnosis but serology is not a timely clinical tool.",
        "PCR best detection method; check availability with commercial and State Public Health Dept. Labs"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Classification"
    },
    {
      "type": "list",
      "items": [
        "Aerobic Gram-negative coccobacilli"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Beta-lactams and clindamycin are not active",
        "Ciprofloxacin",
        "Adult: 400 mg IV q12h (or 750 mg po) bid x 14-21 days",
        "Children: 20-40 mg/kg/day po (max 1.5 gm/day) divided bid (child) Treat for 14-21 days",
        "NOTE: Levofloxacin should work but only limited observational data",
        "IF Critically ill and not responding to monotherapy with ciprofloxacin, reasonable to add either an aminoglycoside or doxycycline:",
        "Gentamicin or Tobramycin 5.1 mg/kg/day IV divided q8h or Streptomycin 10 mg/kg/day IV q12h",
        "Adult: Treat for 10 days",
        "Child: Treat for 5-7 days",
        "Adult: Doxycycline 100 mg IV/po bid x 14-21 days",
        "No discernable efficacy difference. Would be nice to avoid the potential toxicity of aminoglycosides",
        "NOTE: General support for avoiding empiric monotherapy with gentamicin, streptomycin, or tobramycin.",
        "See collected case series in the supplement:",
        "CDC-sponsored supplement: Tularemia: Update on Treatment and Clinical Findings: Clin Infect Dis 2024; 78(:S1): S1-S75",
        "Meningitis is a rare complication:",
        "Reported empiric therapy",
        "(Aminoglycoside) + Doxycycline 100 mg IV/po bid (adult) / 4 mg/kg/d divided q12h IV/po (max. dose 200 mg/day) (child)",
        "(Aminoglycoside) + Ciprofloxacin 400 mg IV (or 750 mg po) q12h (adult) / 20-40 mg/kg/day po (max 1.5 gm/day) divided bid (child)",
        "Treat for 14-21 days"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Less severe illness:",
        "Monotherapy with the same drugs",
        "Adult: Doxycycline 100 mg IV/po bid x 14-21 days or Ciprofloxacin 400 mg IV q12h (or 750 mg po) bid x 14-21 days",
        "Child: Ciprofloxacin 20-40 mg/kg/day po (max 1.5 gm/day) divided bid x 10-14 days",
        "Pregnancy: treatment recommendation is uncertain, but suggest same regimens as above for non-pregnant adults for at least 14 days",
        "Prophylaxis for aerosol exposures (not for natural exposures): Doxycycline 100 mg po bid x 14 days or Ciprofloxacin 500 mg po bid x 14 days"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "There are no controlled clinical trials:",
        "Suggested therapy is based on combination of in vitro activity, infected animal models, and systematic reviews of observational data.",
        "Monotherapy reported effective for mild illness and outpatient therapy: ciprofloxacin or doxycycline",
        "Comination therapy with ciprofloxacin plus doxycycline is favored for hospitalized patients.",
        "Try and avoid aminoglycosides due to risk of nephro- and ototoxicity",
        "Beta-lactam antibiotics are not efficacious.",
        "Doxycycline is bacteriostatic and hence, doxycycline monotherapy may result in relapses.",
        "Large variety of potential complications:",
        "Suppuration of infected regional lymph nodes",
        "Acute renal injury",
        "Rhabdomyolysis",
        "Hepatitis",
        "Empyema",
        "Others: pericarditis, meningitis, osteomyelitis, prosthetic joint infection, and even endocarditis.",
        "Tularemia bioterrorism reference: [N Engl J Med 372:954, 2015](https://www.nejm.org/doi/full/10.1056/NEJMra1401205)."
      ]
    }
  ]
}
